Emmanuel Blot

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness
    E Blot
    DIFEMA Laboratory, Medicine and Pharmacy Faculty, Cedex, France
    Br J Cancer 88:1207-12. 2003
  2. ncbi Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency
    Emmanuel Blot
    Department of Medical Oncology, Institut Curie, 26, rue d Ulm, 75231 Paris Cedex 05, France
    Thromb Res 106:127-30. 2002
  3. ncbi Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics
    E Blot
    Department of Microbiology, Saint Antoine Hospital, Paris, France
    J Hosp Infect 53:187-92. 2003
  4. ncbi Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
    Etienne G C Brain
    Institut Curie, Hôpital René Huguenin, Saint Cloud, France
    Crit Rev Oncol Hematol 80:160-70. 2011
  5. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
  6. ncbi Outpatient oral antibiotics for febrile neutropenic cancer patients
    Matthieu-John Ouvrier
    J Clin Oncol 24:5614; author reply 5614-5. 2006
  7. ncbi Chemoradiotherapy in unresectable squamous cell head and neck cancer
    Emmanuel Blot
    J Clin Oncol 21:3887; author reply 3887-8. 2003
  8. ncbi Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer
    Emmanuel Blot
    N Engl J Med 349:1385-7; author reply 1385-7. 2003
  9. ncbi Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial
    Bojana Pajk
    Institute of Oncology, Zaloska 2, 1000 Ljubljana, Slovenia
    Breast 17:180-5. 2008
  10. ncbi CXCR4 membrane expression in node-negative breast cancer
    Emmanuel Blot
    Departement d Oncologie Medicale, Centre Henri Becquerel, Rue d Amiens, Rouen, France
    Breast J 14:268-74. 2008

Detail Information

Publications10

  1. ncbi Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness
    E Blot
    DIFEMA Laboratory, Medicine and Pharmacy Faculty, Cedex, France
    Br J Cancer 88:1207-12. 2003
    ....
  2. ncbi Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency
    Emmanuel Blot
    Department of Medical Oncology, Institut Curie, 26, rue d Ulm, 75231 Paris Cedex 05, France
    Thromb Res 106:127-30. 2002
    ..The role of ultralarge multimers of Von Willebrand factor in platelet aggregation in the context of metastatic disease is discussed with respect to our findings in this case of cancer-related thrombotic microangiopathy...
  3. ncbi Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics
    E Blot
    Department of Microbiology, Saint Antoine Hospital, Paris, France
    J Hosp Infect 53:187-92. 2003
    ..Serotyping and genotyping showed that several strains were involved in this outbreak, with only two instances of patient-to-patient transmission, involving four and two patients...
  4. ncbi Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial
    Etienne G C Brain
    Institut Curie, Hôpital René Huguenin, Saint Cloud, France
    Crit Rev Oncol Hematol 80:160-70. 2011
    ..This multicentre phase II trial was designed to assess the impact of adjuvant anthracycline-based chemotherapy on these patients' autonomy...
  5. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  6. ncbi Outpatient oral antibiotics for febrile neutropenic cancer patients
    Matthieu-John Ouvrier
    J Clin Oncol 24:5614; author reply 5614-5. 2006
  7. ncbi Chemoradiotherapy in unresectable squamous cell head and neck cancer
    Emmanuel Blot
    J Clin Oncol 21:3887; author reply 3887-8. 2003
  8. ncbi Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer
    Emmanuel Blot
    N Engl J Med 349:1385-7; author reply 1385-7. 2003
  9. ncbi Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial
    Bojana Pajk
    Institute of Oncology, Zaloska 2, 1000 Ljubljana, Slovenia
    Breast 17:180-5. 2008
    ..The anti-tumor activity of capecitabine and vinorelbine seems to be comparable, but the toxicity profiles are different...
  10. ncbi CXCR4 membrane expression in node-negative breast cancer
    Emmanuel Blot
    Departement d Oncologie Medicale, Centre Henri Becquerel, Rue d Amiens, Rouen, France
    Breast J 14:268-74. 2008
    ..Moreover, targeting CXCR4 in primary breast cancer patients may be a new therapeutic concept. However, these results warrant further investigation...